Chapter 1.Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Metabolic Disorder Therapeutics Market, by Disease, 2019-2027 (USD Billion)
1.2.2. Metabolic Disorder Therapeutics Market, by Route of Administration, 2019-2027 (USD Billion)
1.2.3. Metabolic Disorder Therapeutics Market, by Therapy Type, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Metabolic Disorder Therapeutics Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Metabolic Disorder Therapeutics Market Dynamics
3.1. Metabolic Disorder Therapeutics Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Increasing incidences of diabetes and obesity
3.1.1.2. Research and development in the field therapy
3.1.2. Market Challenges
3.1.2.1. High cost of treatment of rare diseases
3.1.3. Market Opportunities
3.1.3.1. Increased expenditure from government and international bodies
Chapter 4. Global Metabolic Disorder Therapeutics Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Metabolic Disorder Therapeutics Market, by Disease
5.1. Market Snapshot
5.2. Global Metabolic Disorder Therapeutics Market by Disease, Performance - Potential Analysis
5.3. Global Metabolic Disorder Therapeutics Market Estimates & Forecasts by Disease 2018-2027 (USD Billion)
5.4. Metabolic Disorder Therapeutics Market, Sub Segment Analysis
5.4.1. Lysosomal Storage Diseases
5.4.2. Diabetes
5.4.3. Obesity
5.4.4. Inherited Metabolic Disorders
5.4.5. Hypercholesterolemia
Chapter 6. Global Metabolic Disorder Therapeutics Market, by Route of Administration
6.1. Market Snapshot
6.2. Global Metabolic Disorder Therapeutics Market by Route of Administration, Performance - Potential Analysis
6.3. Global Metabolic Disorder Therapeutics Market Estimates & Forecasts by Route of Administration 2018-2027 (USD Billion)
6.4. Metabolic Disorder Therapeutics Market, Sub Segment Analysis
6.4.1. Oral Administration
6.4.2. Parenteral Administration
6.4.3. Other route of administration
Chapter 7. Global Metabolic Disorder Therapeutics Market, by Therapy Type
7.1. Market Snapshot
7.2. Global Metabolic Disorder Therapeutics Market by Therapy Type, Performance - Potential Analysis
7.3. Global Metabolic Disorder Therapeutics Market Estimates & Forecasts by Therapy Type 2018-2027 (USD Billion)
7.4. Metabolic Disorder Therapeutics Market, Sub Segment Analysis
7.4.1. Enzyme Replacement Therapy
7.4.2. Cellular Transplantation
7.4.3. Small Molecule-Based Therapy
7.4.4. Substrate Reduction Therapy
7.4.5. Gene Therapy
7.4.6. Drug Therapy
Chapter 8. Global Metabolic Disorder Therapeutics Market, Regional Analysis
8.1. Metabolic Disorder Therapeutics Market, Regional Market Snapshot
8.2. North America Metabolic Disorder Therapeutics Market
8.2.1. U.S. Metabolic Disorder Therapeutics Market
8.2.1.1. Disease breakdown estimates & forecasts, 2018-2027
8.2.1.2. Route of Administration breakdown estimates & forecasts, 2018-2027
8.2.1.3. Therapy Type breakdown estimates & forecasts, 2018-2027
8.2.2. Canada Metabolic Disorder Therapeutics Market
8.3. Europe Metabolic Disorder Therapeutics Market Snapshot
8.3.1. U.K. Metabolic Disorder Therapeutics Market
8.3.2. Germany Metabolic Disorder Therapeutics Market
8.3.3. France Metabolic Disorder Therapeutics Market
8.3.4. Spain Metabolic Disorder Therapeutics Market
8.3.5. Italy Metabolic Disorder Therapeutics Market
8.3.6. Rest of Europe Metabolic Disorder Therapeutics Market
8.4. Asia-Pacific Metabolic Disorder Therapeutics Market Snapshot
8.4.1. China Metabolic Disorder Therapeutics Market
8.4.2. India Metabolic Disorder Therapeutics Market
8.4.3. Japan Metabolic Disorder Therapeutics Market
8.4.4. Australia Metabolic Disorder Therapeutics Market
8.4.5. South Korea Metabolic Disorder Therapeutics Market
8.4.6. Rest of Asia Pacific Metabolic Disorder Therapeutics Market
8.5. Latin America Metabolic Disorder Therapeutics Market Snapshot
8.5.1. Brazil Metabolic Disorder Therapeutics Market
8.5.2. Mexico Metabolic Disorder Therapeutics Market
8.6. Rest of The World Metabolic Disorder Therapeutics Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.3. Novo Nordisk
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Recent Developments
9.3.2. Eli Lilly and Company
9.3.3. Shire Plc
9.3.4. Sanofi
9.3.5. Merck KGaA
9.3.6. AstraZeneca
9.3.7. AbbVie Inc.,
9.3.8. Actelion Pharmaceuticals Ltd
9.3.9. Amgen Inc.,
9.3.10. Biocon
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption